101 related articles for article (PubMed ID: 3350997)
1. The relationship of haloperidol concentrations to therapeutic response.
Perry PJ; Pfohl BM; Kelly MW
J Clin Psychopharmacol; 1988 Feb; 8(1):38-43. PubMed ID: 3350997
[TBL] [Abstract][Full Text] [Related]
2. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
[TBL] [Abstract][Full Text] [Related]
3. Haloperidol: therapeutic window in schizophrenia.
Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder.
Ulrich S; Neuhof S; Braun V; Meyer FP
Pharmacopsychiatry; 1998 Sep; 31(5):163-9. PubMed ID: 9832347
[TBL] [Abstract][Full Text] [Related]
5. Serum haloperidol concentrations and clinical response in acute psychosis.
Miller DD; Hershey LA; Duffy JP; Abernethy DR; Greenblatt DJ
J Clin Psychopharmacol; 1984 Dec; 4(6):305-10. PubMed ID: 6511996
[TBL] [Abstract][Full Text] [Related]
6. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis.
Stevens A; Stevens I; Mahal A; Gaertner HJ
Pharmacopsychiatry; 1992 Nov; 25(6):273-7. PubMed ID: 1494594
[TBL] [Abstract][Full Text] [Related]
7. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
Magliozzi JR; Hollister LE; Arnold KV; Earle GM
Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
[TBL] [Abstract][Full Text] [Related]
8. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
9. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
Abuzzahab FS; Zimmerman RL
J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
[TBL] [Abstract][Full Text] [Related]
10. Serum prolactin as a correlate of clinical response to haloperidol.
Van Putten T; Marder SR; Mintz J
J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
[TBL] [Abstract][Full Text] [Related]
11. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
12. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
13. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
Yasui-Furukori N; Saito M; Nakagami T; Kaneda A; Tateishi T; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):286-91. PubMed ID: 16386826
[TBL] [Abstract][Full Text] [Related]
14. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
[TBL] [Abstract][Full Text] [Related]
15. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics.
Perry PJ; Miller DD; Arndt SV; Smith DA; Holman TL
J Clin Psychopharmacol; 1993 Feb; 13(1):46-51. PubMed ID: 8486817
[TBL] [Abstract][Full Text] [Related]
16. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder.
Volavka J; Cooper TB; Czobor P; Meisner M
Psychopharmacol Bull; 1996; 32(1):75-9. PubMed ID: 8927679
[TBL] [Abstract][Full Text] [Related]
17. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
Contreras S; Alexander H; Faber R; Bowden C
J Clin Psychopharmacol; 1987 Apr; 7(2):95-8. PubMed ID: 3584527
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
[TBL] [Abstract][Full Text] [Related]
19. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
[TBL] [Abstract][Full Text] [Related]
20. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
Reschke RW
Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]